Guideline
Razi Journal of Medical Sciences (Razi J Med Sci) is a Continuous, open access, peer-reviewed multidisciplinary medical publication that welcomes contributions particularly biomedical experiences and clinical investigations on prevalent diseases as well as analyses of factors that may modulate the incidence, course, and management of diseases and pertinent medical problems. The basic science articles related to the clinic will be wellcomed. Manuscripts with didactic orientation and subjects exclusively of local interest will not be considered for publication
Cover Letter
Make sure you register for an ORCID iD and associate it with your manuscript when you submit. This will ensure that your published article is listed on your ORCID record. On the other hand, it helps us see the previous publications of the author(s). This takes less than 5 minutes to complete. Find more information here.
Article languge
Razi journal of medical sciences (Razi J Med Sci) is published in both Persian and English. Razi Magazine also accepts English articles from non-Persian speaking countries. Of course, for non-Iranian writers, a Persian abstract taken from the original text is prepared by Razi J Med Sci scientific secretaries under the supervision of the editor in-chief and is loaded next to the English text. Persian articles also need to send an extended abstract along with the English abstract.
Article types and requirements
We strongly recommend that each manuscript should be submitted with a cover letter, in which authors clearly describe why their work is novel and deserves to be published in Razi J Med Sci. This should be uploaded as a separate file during submission process, entitled ‘Cover Letter’. You can download the Cover Letter template here.
ORCID iD
Background and Aim: Describes the background and purpose of the study.
Materials and Methods. Type of study. Define study groups. Techniques used in the study. For animal models (in vivo) or cell culture-based experiments (in vitro) specify the species and cell lines, respectively.
Materials and Methods section should provide enough detail for others to be able to replicate the study. If you have more than one method, use subsections with relevant headings, e.g. different models, in vitro and in vivo studies, materials and reagents, etc.
Statistical analysis section should be supplied as a separate paragraph containing statistical software and tests used for data analysis.
Results section may be divided into subsections or may be combined. Provide P-values and other statistical explanations for the findings. No interpretation of data is allowed.
Discussion: Discuss the findings and compare the data with others’ studies without P-values. The name of the first author in a research study should accompany by et al. The limitations of the study should be mentioned in the last paragraph of the study.
Conclusions clearly explain the main conclusions of the article, highlighting its importance and relevance, and future clinical use of the study.
• Title: Should be informative, brief, and concise. Length less than 110 characters. No words in the parenthesis. Avoid using abbreviation except for routine words such as DNA or CD4. Our default understanding is human studies, if experiments have been done in animal models (in vivo) or cell culture-based experiments (in vitro) the species and cell lines should be mentioned in the title, respectively.
• Short title (Running head): Should be less than 50 characters not exactly the title details. Prune the title to harvest a brief short title.
Abstract: 200 words of unstructured summary (On the contrary to the original article, which was structured).
Case presentation: Type of study. Define study groups. Techniques used in the study. For animal models (in vivo) or cell culture-based experiments (in vitro) specify the species and cell lines, respectively.
Conclusions: Provides a thoughtful end to the manuscript. Summarize or wrap up the paper's main points. A conclusion is what you will carve into the reader’s mind.
Case presentation section should provide enough information on the presented case.
Laboratory findings section should be supplied as a separate paragraph for laboratory or other paraclinical data.
Conclusions clearly explain the main conclusions of the article, highlighting its importance and relevance, and future clinical use of the study.
• Title: Should be informative, brief, and concise. Length less than 110 characters.
References
All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order
**Please keep in mind that figures and tables should be supplied at the end of the manuscript but supporting information should be supplied as a separate file entitled supplementary file. Furthermore, Figures submitted in color will be reproduced free of charge **.
Figures
Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.
Figure Legends
Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.
Tables
Tables should be self-contained and complement, should not duplicate the information contained in the text. They should be supplied as editable files at the end of the manuscript text before references. The should not be copy pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.
Supplementary materials
Supplementary materials are the additional parts to a manuscript, such as audio files, video clips, or datasets that might be of interest to readers. Authors can submit one file of supplementary material along with their manuscript through the Manuscript Tracking System.
Acknowledgments
Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Appreciating anonymous or potential reviewers is not allowed.
Declarations
Conflict of Interest
Authors will be strongly asked to provide a conflict of interest statement during the submission process. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement. The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors.
Funding/Support
Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation.
Authorship
The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:
1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; and
2. Been involved in drafting the manuscript or revising it critically for important intellectual content; and
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.
Additional Authorship Options. Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’
Ethical guidelines
In any studies on human or animal subjects, the following ethical guidelines must be observed. For any experiments on humans, all work must be conducted in accordance with the Declaration of Helsinki (1964). Manuscripts describing experimental work which carries a risk of harm to human subjects must include a statement that the experiment was conducted with the human subjects’ understanding and consent, as well as a statement that the responsible Ethical Committee has approved the experiments. In the case of any animal experiments, the authors must provide a full description of any anesthetic or surgical procedure used, as well as evidence that all possible steps were taken to avoid animal suffering at each stage of the experiment.
Who Is an Author?
Razi J Med Sci considers the following criteria necessary for the authors of submitted articles based on the ICMJE recommendations: The ICMJE recommends that authorship be based on the following 4 criteria:
(https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two)
Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained
Publication Ethics
Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. The principles of ethics in the journal are observed according to the COPE (Committee on Publication Ethics).
Research and Publication Misconduct Management Process
The Editor-in-Chief will investigate misconduct possibility such as duplication, plagiarism, fabricated results, fake authorship, fake reviewer, undisclosed conflicts of interest, and ethical problems with a submitted paper, salami publication, complaints against editor in chief/ associate editors or advisory board or reviewers.
Peer-Reviewing
Initially all papers are first reviewed by an editorial committee consisting of 3 or more members of the editorial team to ensure their appropriateness and relevance to the framework of the journal. The prime purpose is to decide whether to send a paper for peer review and to give a rapid decision on those that are not. Papers which do not meet basic standards or are unlikely to be published irrespective of a positive peer review, for example because their novel contribution is insufficient or the relevance to the discipline is unclear, may be rejected at this point in order to avoid delays to authors who may wish to seek publication elsewhere Manuscripts are also excluded by the editors if there are major faults in the methodology of research. . Authors can expect a decision from this stage of the review process within 2 weeks of submission. Manuscripts going forward to the review process are handled anonymously and comments are discussed in weekly editorial sessions. Reviews are then sent to the corresponding authors for proposed modifications and the new version of the manuscript would be peer-reviewed for a second time by one or two external reviewers. We aim to complete the review process within 6 weeks of the decision to review although occasionally delays do happen and authors should allow at least 8 weeks from submissions before contacting the journal. The Editor-in-Chief reserves the right to the final decision regarding acceptance
Reporting guidelines
Authors are strongly encouraged to use appropriate reporting guidelines when preparing and submitting manuscripts, to maximise transparency and reproducibility. Our editors and reviewers are also encouraged to use them in the review process. Completed checklists should be provided in the supplementary files on submission. We particularly encourage the use of:
CONSORT for randomized controlled trials
TREND for non-randomized trials
PRISMA for systematic review and meta-analyses
CARE for case reports
STROBE for observational studies
STREGA for genetic association studies
SRQR for qualitative studies
STARD for diagnostic accuracy studies
ARRIVE for animal experiments
Appeals
Authors may appeal if they feel that the decision to reject was based on: i) a major misunderstanding over a technical aspect of the manuscript, or ii) a failure understand the scientific advance shown by the manuscript. Appeals requesting a second opinion without sufficient justification will not be considered. To lodge an appeal, please contact the journal by email, quoting your manuscript number. Appeals will only be considered from the original submitting author.
Extended Abstract
Extended abstract is mandatory for Persian papers. In original and review articles extended abstract should be structures as: Introduction, Material and Method, Results, Discussion and Conclusion but sutructures extended abstract is not needed for letter to editor and case reports. The number of words in original and review articles should be 1200 to 1500 and letter to the editor and case report should be 600 to 800 words.
Manuscript Revision
Revised manuscripts must include the following items:
Responses to Comments that includes numbered point-by-point responses (you can download an example of a point by point reply) to the comments made by the Reviewers, Editor, and Editorial Office labeled as 'COMMENT' and 'RESPONSE' for each item.
Marked Manuscript. Any text that was not part of the original manuscript but has now been added, underline formatting should be applied; to any text that was part of the original manuscript but has now been deleted, strikethrough formatting should be applied. Changes made on Figures and Tables should be clearly visible and provided as separate files labeled as 'Figure x Marked' and 'Table x Marked'. Line numbering should be used in the Marked Manuscript and numbers mentioned in the point-by-point response to the comments.
Unmarked Manuscript. The Unmarked Manuscript should be your revised manuscript just as you intend it for publication (if it is accepted). Any table and figure that is to be part of your revised manuscript should be provided as a separate file (e.g., 'Figure x-Unmarked' or 'Table x- Unmarked'). Line numbering need not be used in the Unmarked Manuscript too.
Copyright
Razi J Med Sci is Published by Iran University of Medical Sciences, This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc-sa/4.0/ ), which permits to: copy and redistribute the material in any medium or format, remix, transform, and build upon the material. The licensor cannot revoke these freedoms as long as you follow the license terms.
Please consider that RJMS was published under the license CC BY-NC-SA-1.0 until July 2018, from August 2018, since September 2023, it was published with CC BY-NC-SA 3.0 and after changing to a continuous manner in October 2023, it is published under the license of CC BY-NC-SA 4.0
Proofs
Corrected proofs must be returned to the publisher within two to three days of receipt. The publisher will do everything possible to ensure prompt publication.
How to access
The journal provides immediate free access to its scientific contents and does not charge the authors fee for submission, processing or publication of the manuscripts.
Language editing
Razi J Med Sci has partnered with Editage to provide an English-language editing service to authors prior to submission. Authors that wish to use this service will receive a 10% discount on all editing services provided by Editage. To find out more information or get a quote, please click here.
Authors’ contributions: The individual contributions of authors to the manuscript should be specified. The authors’ name should be abbreviated in this section (e.g. JMS for John Miller Smith).
Article Publishing Charges:
Razi journal Of Medical Sciences (Razi J Med Sci) does not charge for accepting articles and publishing articles is free.
Cover Letter
Make sure you register for an ORCID iD and associate it with your manuscript when you submit. This will ensure that your published article is listed on your ORCID record. On the other hand, it helps us see the previous publications of the author(s). This takes less than 5 minutes to complete. Find more information here.
Article languge
Razi journal of medical sciences (Razi J Med Sci) is published in both Persian and English. Razi Magazine also accepts English articles from non-Persian speaking countries. Of course, for non-Iranian writers, a Persian abstract taken from the original text is prepared by Razi J Med Sci scientific secretaries under the supervision of the editor in-chief and is loaded next to the English text. Persian articles also need to send an extended abstract along with the English abstract.
Article types and requirements
We strongly recommend that each manuscript should be submitted with a cover letter, in which authors clearly describe why their work is novel and deserves to be published in Razi J Med Sci. This should be uploaded as a separate file during submission process, entitled ‘Cover Letter’. You can download the Cover Letter template here.
ORCID iD
Original article
We encourage high quality original manuscripts providing scientists with novel ideas or information in medical research.
Title: should be informative, brief, and concise. Length less than 100 characters. No words in the parenthesis. Avoid using abbreviation except for routine words such as DNA or CD4. Our default understanding is human studies, if experiments have been done in animal models (in vivo) or cell culture-based experiments (in vitro) the species and cell lines should be mentioned in the title, respectively.
Short title (Running head): Should be less than 50 characters not exactly the title. Prune the title to harvest a brief short title.
Authors queue: Author names, affiliations in numeric order, corresponding author’s information (academic email, phone number (Tel/fax), address and postal code should be listed in the beginning of the abstract.
Abstract: 250 words structured as follows (Note that non-Persian speaking countries articles need a 250 word abstract, but articles from Persian speaking countries do not need a 250 word abstract and should use an extended abstract instead):Background and Aim: Describes the background and purpose of the study.
Materials and Methods. Type of study. Define study groups. Techniques used in the study. For animal models (in vivo) or cell culture-based experiments (in vitro) specify the species and cell lines, respectively.
Provide only the primary outcomes with P-value. Do not discuss the findings.
Conclusions. Provides a thoughtful end to the manuscript. Summarize or wrap up the paper's main points. A conclusion is what you will carve into the reader’s mind.
Up to 6, provided in alphabetical order.
Main body of the manuscript: The text is limited to: less than 3,500 words not including abstract, figure legends and references (please supply a word count). Informative headings and subheadings should be provided throughout the manuscript. Up to 5 figures and 3 tables. Additional unlimited online information can be provided as supplementary file. Up to 50 references are allowed.
Background section should be succinct, with no subheadings.Materials and Methods section should provide enough detail for others to be able to replicate the study. If you have more than one method, use subsections with relevant headings, e.g. different models, in vitro and in vivo studies, materials and reagents, etc.
Statistical analysis section should be supplied as a separate paragraph containing statistical software and tests used for data analysis.
Results section may be divided into subsections or may be combined. Provide P-values and other statistical explanations for the findings. No interpretation of data is allowed.
Discussion: Discuss the findings and compare the data with others’ studies without P-values. The name of the first author in a research study should accompany by et al. The limitations of the study should be mentioned in the last paragraph of the study.
Conclusions clearly explain the main conclusions of the article, highlighting its importance and relevance, and future clinical use of the study.
Review article
Reviews should present an update of the most recent developments in medical research based on recent original studies. We welcome the submission of high quality color pictures, which may improve the understanding of the article.• Title: Should be informative, brief, and concise. Length less than 110 characters. No words in the parenthesis. Avoid using abbreviation except for routine words such as DNA or CD4. Our default understanding is human studies, if experiments have been done in animal models (in vivo) or cell culture-based experiments (in vitro) the species and cell lines should be mentioned in the title, respectively.
• Short title (Running head): Should be less than 50 characters not exactly the title details. Prune the title to harvest a brief short title.
Abstract: 200 words of unstructured summary (On the contrary to the original article, which was structured).
Keywords: Up to 6, provided in alphabetical order.
• Main body of the manuscript: The text is limited to: less than 4,500 words not including abstract, figure legends and references (please supply a word count). Informative headings and subheadings should be provided throughout the manuscript. Up to 7 figures and 4 tables. Additional unlimited online information can be provided as supplementary file. Up to 100 references are allowed.
Case Report
We encourage high quality case reports providing scientists with newly emerged diseases or new information on disease management.
Title: Similar to the original article.
Short title (Running head): Similar to the original article.
Authors queue: Similar to the original article.
Abstract: 150 words structured as follows:
Background and Aim: Describes the background and purpose of the study.Case presentation: Type of study. Define study groups. Techniques used in the study. For animal models (in vivo) or cell culture-based experiments (in vitro) specify the species and cell lines, respectively.
Conclusions: Provides a thoughtful end to the manuscript. Summarize or wrap up the paper's main points. A conclusion is what you will carve into the reader’s mind.
Up to 5, provided in alphabetical order.
Main body of the manuscript: The text is limited to: less than 2,000 words not including abstract, figure legends and references (please supply a word count). Up to 3 figures and 2 tables. Additional unlimited online information can be provided as supplementary file. Up to 50 references are allowed.
Background section should be succinct, with no subheadings.Case presentation section should provide enough information on the presented case.
Laboratory findings section should be supplied as a separate paragraph for laboratory or other paraclinical data.
Conclusions clearly explain the main conclusions of the article, highlighting its importance and relevance, and future clinical use of the study.
Letters to the Editor
Letters to the Editor are brief reports that can be preliminary, but may represent original observations that may have a substantial impact within “Medical research”. They will be subject to peer review and should begin with the salutation “Dear Editor”. There should not be any separate abstract, but rather a conclusion paragraph sums up the Letter.• Title: Should be informative, brief, and concise. Length less than 110 characters.
Main body of the manuscript: The text is strictly limited to maximum 1000 words. Maximum 10 references are allowed. Up to 2 figures and/or tables are allowed. Figure legends should not be more than 100 words. Online supplementary file can be included for more references, detailed explanations of methods, sequencing databases, tables and figures.
Correspondence
Correspondences that refer to a previously published original article are welcome to be published in Razi J Med Sci. The text of a correspondence is strictly limited to less than 700 words (please supply a word count). Up to 6 references and one of the references must be to the article discussed. One figure and/or table. Procedure: The correspondence will be sent to the author of the article, who will have 4 weeks to answer. The correspondence and the authors’ response will be published in the same issue.References
All references should be numbered consecutively in order of appearance and should be as complete as possible. In text citations should cite references in consecutive order
**Please keep in mind that figures and tables should be supplied at the end of the manuscript but supporting information should be supplied as a separate file entitled supplementary file. Furthermore, Figures submitted in color will be reproduced free of charge **.
Figures
Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted.
Figure Legends
Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.
Tables
Tables should be self-contained and complement, should not duplicate the information contained in the text. They should be supplied as editable files at the end of the manuscript text before references. The should not be copy pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.
Supplementary materials
Supplementary materials are the additional parts to a manuscript, such as audio files, video clips, or datasets that might be of interest to readers. Authors can submit one file of supplementary material along with their manuscript through the Manuscript Tracking System.
Acknowledgments
Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Appreciating anonymous or potential reviewers is not allowed.
Declarations
Conflict of Interest
Authors will be strongly asked to provide a conflict of interest statement during the submission process. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement. The journal requires that all authors disclose any potential sources of conflict of interest. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript. Potential sources of conflict of interest include, but are not limited to: patent or stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker's fees from a company. The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors.
Funding/Support
Authors should list all funding sources in the Acknowledgments section. Authors are responsible for the accuracy of their funder designation.
Authorship
The list of authors should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:
1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; and
2. Been involved in drafting the manuscript or revising it critically for important intellectual content; and
3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and
4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.
Additional Authorship Options. Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’
Ethical guidelines
In any studies on human or animal subjects, the following ethical guidelines must be observed. For any experiments on humans, all work must be conducted in accordance with the Declaration of Helsinki (1964). Manuscripts describing experimental work which carries a risk of harm to human subjects must include a statement that the experiment was conducted with the human subjects’ understanding and consent, as well as a statement that the responsible Ethical Committee has approved the experiments. In the case of any animal experiments, the authors must provide a full description of any anesthetic or surgical procedure used, as well as evidence that all possible steps were taken to avoid animal suffering at each stage of the experiment.
Who Is an Author?
Razi J Med Sci considers the following criteria necessary for the authors of submitted articles based on the ICMJE recommendations: The ICMJE recommends that authorship be based on the following 4 criteria:
(https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two)
Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
Drafting the work or reviewing it critically for important intellectual content; AND
Final approval of the version to be published; AND
Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Informed consent and patient detailsStudies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained
Publication Ethics
Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. The principles of ethics in the journal are observed according to the COPE (Committee on Publication Ethics).
Research and Publication Misconduct Management Process
The Editor-in-Chief will investigate misconduct possibility such as duplication, plagiarism, fabricated results, fake authorship, fake reviewer, undisclosed conflicts of interest, and ethical problems with a submitted paper, salami publication, complaints against editor in chief/ associate editors or advisory board or reviewers.
Peer-Reviewing
Initially all papers are first reviewed by an editorial committee consisting of 3 or more members of the editorial team to ensure their appropriateness and relevance to the framework of the journal. The prime purpose is to decide whether to send a paper for peer review and to give a rapid decision on those that are not. Papers which do not meet basic standards or are unlikely to be published irrespective of a positive peer review, for example because their novel contribution is insufficient or the relevance to the discipline is unclear, may be rejected at this point in order to avoid delays to authors who may wish to seek publication elsewhere Manuscripts are also excluded by the editors if there are major faults in the methodology of research. . Authors can expect a decision from this stage of the review process within 2 weeks of submission. Manuscripts going forward to the review process are handled anonymously and comments are discussed in weekly editorial sessions. Reviews are then sent to the corresponding authors for proposed modifications and the new version of the manuscript would be peer-reviewed for a second time by one or two external reviewers. We aim to complete the review process within 6 weeks of the decision to review although occasionally delays do happen and authors should allow at least 8 weeks from submissions before contacting the journal. The Editor-in-Chief reserves the right to the final decision regarding acceptance
Reporting guidelines
Authors are strongly encouraged to use appropriate reporting guidelines when preparing and submitting manuscripts, to maximise transparency and reproducibility. Our editors and reviewers are also encouraged to use them in the review process. Completed checklists should be provided in the supplementary files on submission. We particularly encourage the use of:
CONSORT for randomized controlled trials
TREND for non-randomized trials
PRISMA for systematic review and meta-analyses
CARE for case reports
STROBE for observational studies
STREGA for genetic association studies
SRQR for qualitative studies
STARD for diagnostic accuracy studies
ARRIVE for animal experiments
Appeals
Authors may appeal if they feel that the decision to reject was based on: i) a major misunderstanding over a technical aspect of the manuscript, or ii) a failure understand the scientific advance shown by the manuscript. Appeals requesting a second opinion without sufficient justification will not be considered. To lodge an appeal, please contact the journal by email, quoting your manuscript number. Appeals will only be considered from the original submitting author.
Extended Abstract
Extended abstract is mandatory for Persian papers. In original and review articles extended abstract should be structures as: Introduction, Material and Method, Results, Discussion and Conclusion but sutructures extended abstract is not needed for letter to editor and case reports. The number of words in original and review articles should be 1200 to 1500 and letter to the editor and case report should be 600 to 800 words.
Manuscript Revision
Revised manuscripts must include the following items:
Responses to Comments that includes numbered point-by-point responses (you can download an example of a point by point reply) to the comments made by the Reviewers, Editor, and Editorial Office labeled as 'COMMENT' and 'RESPONSE' for each item.
Marked Manuscript. Any text that was not part of the original manuscript but has now been added, underline formatting should be applied; to any text that was part of the original manuscript but has now been deleted, strikethrough formatting should be applied. Changes made on Figures and Tables should be clearly visible and provided as separate files labeled as 'Figure x Marked' and 'Table x Marked'. Line numbering should be used in the Marked Manuscript and numbers mentioned in the point-by-point response to the comments.
Unmarked Manuscript. The Unmarked Manuscript should be your revised manuscript just as you intend it for publication (if it is accepted). Any table and figure that is to be part of your revised manuscript should be provided as a separate file (e.g., 'Figure x-Unmarked' or 'Table x- Unmarked'). Line numbering need not be used in the Unmarked Manuscript too.
Copyright
Razi J Med Sci is Published by Iran University of Medical Sciences, This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc-sa/4.0/ ), which permits to: copy and redistribute the material in any medium or format, remix, transform, and build upon the material. The licensor cannot revoke these freedoms as long as you follow the license terms.
Please consider that RJMS was published under the license CC BY-NC-SA-1.0 until July 2018, from August 2018, since September 2023, it was published with CC BY-NC-SA 3.0 and after changing to a continuous manner in October 2023, it is published under the license of CC BY-NC-SA 4.0
Proofs
Corrected proofs must be returned to the publisher within two to three days of receipt. The publisher will do everything possible to ensure prompt publication.
How to access
The journal provides immediate free access to its scientific contents and does not charge the authors fee for submission, processing or publication of the manuscripts.
Language editing
Razi J Med Sci has partnered with Editage to provide an English-language editing service to authors prior to submission. Authors that wish to use this service will receive a 10% discount on all editing services provided by Editage. To find out more information or get a quote, please click here.
Authors’ contributions: The individual contributions of authors to the manuscript should be specified. The authors’ name should be abbreviated in this section (e.g. JMS for John Miller Smith).
Article Publishing Charges:
Razi journal Of Medical Sciences (Razi J Med Sci) does not charge for accepting articles and publishing articles is free.
View: 18326 Time(s) | Print: 6892 Time(s) | Email: 115 Time(s) |
0 Comment(s)
